Welcome to our dedicated page for Eloxx Pharmaceuticals news (Ticker: ELOX), a resource for investors and traders seeking the latest updates and insights on Eloxx Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Eloxx Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Eloxx Pharmaceuticals's position in the market.
ELX-02, administered at 1.5mg/kg/day, showed a significant mean reduction of 5.4mmol/L in sweat chloride levels, indicating potential CFTR activity restoration in cystic fibrosis patients. The results support moving ELX-02 into Phase 3 trials. The FDA has granted Fast Track and Orphan Drug Designations for ELX-02. Additionally, the company has started a Phase 2 expansion for ELX-02 combined with ivacaftor, with results anticipated by mid-2022. Eloxx aims to explore inhaled delivery of ELX-02 to enhance efficacy.
Eloxx Pharmaceuticals (NASDAQ: ELOX) reported its Q3 2021 results, posting a net loss of $9.9 million, up from $6.6 million in Q3 2020. The company is progressing with its Phase 2 ELX-02 clinical trials for cystic fibrosis, expecting data in late 2021. ELX-02 received FDA Fast Track designation, highlighting its potential for serious medical needs. Eloxx entered a debt facility with Hercules Capital for up to $30 million, drawing an initial $12.5 million. As of September 30, 2021, cash reserves stood at $52.4 million, projected to last through Q1 2023.
Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) will host an Investor and Analyst call on October 12, 2021, featuring Dr. Eitan Kerem, a prominent cystic fibrosis (CF) expert. The call aims to provide updates on the company’s CF programs as data from ongoing Phase 2 trials are expected in Q4 2021. The call is scheduled for 10:00 a.m. ET, with both domestic and international dial-in options available. The event will be webcast live and accessible on the company's website, with a replay available for 30 days afterwards.
Eloxx Pharmaceuticals (Nasdaq: ELOX) has secured a debt facility of up to $30 million from Hercules Capital, of which $12.5 million has been drawn to fully repay existing debts. The remaining funds will be available in tranches based on specific clinical milestones. This non-dilutive financing is aimed at advancing Eloxx’s product pipeline, notably ELX-02, currently in Phase 2 trials for cystic fibrosis. CEO Sumit Aggarwal expressed confidence in the partnership with Hercules to support their clinical and preclinical programs.
Eloxx Pharmaceuticals (Nasdaq: ELOX) has received Fast Track designation from the FDA for its drug candidate ELX-02, aimed at treating cystic fibrosis patients with nonsense mutations. This designation, announced on September 9, 2021, facilitates expedited development and review processes, allowing for greater FDA interaction. ELX-02 is currently in Phase 2 clinical trials, designed to assess safety and efficacy. Data from initial treatment arms are expected in Q4 2021. The drug has also previously received orphan drug designations from both the FDA and EMA.
Eloxx Pharmaceuticals has appointed Dr. Ali Hariri as Chief Medical Officer, focusing on clinical development of its pipeline targeting rare diseases. Previously at Sanofi, Dr. Hariri's experience in rare diseases will aid in advancing ELX-02, currently in Phase 2 trials for cystic fibrosis patients with nonsense mutations. The company expects data from the first four treatment arms of the Phase 2 study in Q4 2021, emphasizing the safety and biological activity of ELX-02.
Eloxx Pharmaceuticals (NASDAQ: ELOX) announced progress in its clinical programs, including updates on ELX-02 Phase 2 trials for cystic fibrosis (CF) and the nomination of ZKN-013 for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and Junctional Epidermolysis Bullosa (JEB). The company raised approximately $52 million through a public offering and received $2.6 million from the Cystic Fibrosis Foundation for developing Ribosome Modulating Agents (RMAs). Financial results show a net loss of $36.1 million for Q2 2021, with cash reserves of $56.7 million expected to fund operations into Q1 2023.
Eloxx Pharmaceuticals (NASDAQ: ELOX) announced an update on its ongoing Phase 2 clinical program for ELX-02, targeting cystic fibrosis in patients with the G542X allele. Patient enrollment is on track, with data from the first four treatment arms expected in Q4 2021. Currently, the trial has no reported serious drug-related adverse events, and a fifth treatment arm has been added to evaluate ELX-02 with Kalydeco. The program is partially funded by the Cystic Fibrosis Foundation, and ELX-02 has received orphan drug designation from the FDA.
Eloxx Pharmaceuticals (NASDAQ: ELOX) has been awarded up to $2.6M from the Cystic Fibrosis Foundation to develop oral Ribosome Modulating Agents (RMAs) targeting cystic fibrosis patients with nonsense mutations. The funding supports the TURBO-ZM™ synthetic chemistry platform, enhancing the ongoing ELX-02 program in Phase 2 clinical trials. CEO Sumit Aggarwal highlights the importance of this funding for advancing novel therapies. Results from the Phase 2 trials are expected later this year, reflecting the company's commitment to addressing rare genetic diseases.
Eloxx Pharmaceuticals has successfully closed an underwritten public offering of 38,333,334 shares of common stock at a price of $1.35 per share, totaling approximately $51.75 million in gross proceeds. This includes the full exercise of an underwriters’ option for an additional 5,000,000 shares. The offering was managed by B. Riley Securities, Inc. A shelf registration statement was previously approved by the SEC. The press release also contains forward-looking statements highlighting potential risks and uncertainties affecting the company’s future performance.